Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 ...

VESPER-2 is a 28-week Phase 2b clinical trial assessing the efficacy and tolerability of different weekly doses of MET-097i with or without titration. The trial enrolled the first participant in March ...

Convertible securities provide financing or cash to companies in need. But their setup can be problematic if converted at ...

The STRF sale is scheduled to close later on Tuesday, with Strategy raising approximately $711 million in net proceeds.

Microchip Technology Incorporated (“Microchip” or the “Company”), a leading provider of smart, connected, and secure embedded ...

Star continues to hold the 9,024,035 shares of Enservco common stock and 3,476,965 shares of 2.0% Cumulative Mandatorily Convertible Series A Preferred stock and remains in contact with Enservco ...

Holders of the depositary shares will be entitled to a proportional fractional interest in the rights and preferences of the ...

The world's largest corporate holder of bitcoin is looking to raise around $500 million in an offering of Perpetual Preferred ...

STRK provides fixed 8.00% income with optional future conversion into MSTR common stock. At-the-market offering allows gradual capital raising based on market price and volume.

Strike (STRK), the preferred stock ... dividend payments than common stock owners if the company makes them and also to the company's assets in the event of a liquidation. STRK is a perpetual ...

With a $21 billion preferred stock issuance, Strategy takes a calculated step toward expanding its Bitcoin portfolio amid fluctuating regulatory and economic conditions. Strategy taps alternative ...